Annual SGA
$17.70 M
-$8.32 M-31.97%
December 31, 2023
Summary
- As of February 20, 2025, QNCX annual SGA is $17.70 million, with the most recent change of -$8.32 million (-31.97%) on December 31, 2023.
- During the last 3 years, QNCX annual SGA has risen by +$109.00 thousand (+0.62%).
- QNCX annual SGA is now -40.06% below its all-time high of $29.52 million, reached on December 31, 2021.
Performance
QNCX SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$3.63 M
-$1.06 M-22.68%
September 30, 2024
Summary
- As of February 20, 2025, QNCX quarterly SGA is $3.63 million, with the most recent change of -$1.06 million (-22.68%) on September 30, 2024.
- Over the past year, QNCX quarterly SGA has dropped by -$1.28 million (-26.05%).
- QNCX quarterly SGA is now -60.14% below its all-time high of $9.11 million, reached on March 31, 2022.
Performance
QNCX Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$1.37 B
-$53.26 M-4.04%
September 30, 2024
Summary
- As of February 20, 2025, QNCX TTM SGA is -$1.37 billion, with the most recent change of -$53.26 million (-4.04%) on September 30, 2024.
- Over the past year, QNCX TTM SGA has dropped by -$1.39 billion (-7888.15%).
- QNCX TTM SGA is now -4082.71% below its all-time high of -$32.83 million.
Performance
QNCX TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
QNCX Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -32.0% | -26.1% | -7888.1% |
| 3 y3 years | +0.6% | -26.1% | -7888.1% |
| 5 y5 years | +770.0% | -26.1% | -7888.1% |
QNCX Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -40.1% | at low | -60.1% | +2.2% | -69.3% | at low |
| 5 y | 5-year | -40.1% | +97.6% | -60.1% | +24.2% | -543.7% | at low |
| alltime | all time | -40.1% | +1292.2% | -60.1% | +946.1% | -4082.7% | at low |
Quince Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $3.63 M(-22.7%) | $18.20 M(-5.4%) |
| Jun 2024 | - | $4.70 M(-5.6%) | $19.24 M(+2.5%) |
| Mar 2024 | - | $4.97 M(+1.3%) | $18.77 M(+6.5%) |
| Dec 2023 | $17.70 M(-32.0%) | $4.91 M(+5.3%) | $17.63 M(+8.3%) |
| Sep 2023 | - | $4.66 M(+10.2%) | $16.27 M(+2.0%) |
| Jun 2023 | - | $4.23 M(+10.6%) | $15.95 M(-23.2%) |
| Mar 2023 | - | $3.83 M(+7.7%) | $20.78 M(-20.3%) |
| Dec 2022 | $26.01 M(-11.9%) | $3.55 M(-18.3%) | $26.06 M(-15.5%) |
| Sep 2022 | - | $4.34 M(-52.0%) | $30.84 M(-9.7%) |
| Jun 2022 | - | $9.06 M(-0.5%) | $34.13 M(+6.2%) |
| Mar 2022 | - | $9.11 M(+9.3%) | $32.14 M(+8.9%) |
| Dec 2021 | $29.52 M | $8.33 M(+9.1%) | $29.52 M(+12.7%) |
| Sep 2021 | - | $7.64 M(+8.1%) | $26.19 M(+11.5%) |
| Jun 2021 | - | $7.06 M(+8.9%) | $23.48 M(+14.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | $6.49 M(+29.9%) | $20.60 M(+17.1%) |
| Dec 2020 | $17.59 M(+96.4%) | $5.00 M(+1.3%) | $17.59 M(+13.4%) |
| Sep 2020 | - | $4.93 M(+17.8%) | $15.51 M(+20.3%) |
| Jun 2020 | - | $4.18 M(+20.3%) | $12.90 M(+15.4%) |
| Mar 2020 | - | $3.48 M(+19.0%) | $11.18 M(+24.9%) |
| Dec 2019 | $8.95 M(+340.2%) | $2.92 M(+26.2%) | $8.95 M(+32.1%) |
| Sep 2019 | - | $2.32 M(-6.1%) | $6.78 M(+34.3%) |
| Jun 2019 | - | $2.47 M(+97.3%) | $5.05 M(+71.8%) |
| Mar 2019 | - | $1.25 M(+67.6%) | $2.94 M(+44.4%) |
| Dec 2018 | $2.03 M(+60.0%) | $746.00 K(+27.7%) | $2.03 M(+57.9%) |
| Sep 2018 | - | $584.00 K(+63.6%) | $1.29 M(+83.0%) |
| Jun 2018 | - | $357.00 K(+2.9%) | $704.00 K(+102.9%) |
| Mar 2018 | - | $347.00 K | $347.00 K |
| Dec 2017 | $1.27 M | - | - |
FAQ
- What is Quince Therapeutics annual SGA?
- What is the all time high annual SGA for Quince Therapeutics?
- What is Quince Therapeutics annual SGA year-on-year change?
- What is Quince Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Quince Therapeutics?
- What is Quince Therapeutics quarterly SGA year-on-year change?
- What is Quince Therapeutics TTM SGA?
- What is the all time high TTM SGA for Quince Therapeutics?
- What is Quince Therapeutics TTM SGA year-on-year change?
What is Quince Therapeutics annual SGA?
The current annual SGA of QNCX is $17.70 M
What is the all time high annual SGA for Quince Therapeutics?
Quince Therapeutics all-time high annual SGA is $29.52 M
What is Quince Therapeutics annual SGA year-on-year change?
Over the past year, QNCX annual SGA has changed by -$8.32 M (-31.97%)
What is Quince Therapeutics quarterly SGA?
The current quarterly SGA of QNCX is $3.63 M
What is the all time high quarterly SGA for Quince Therapeutics?
Quince Therapeutics all-time high quarterly SGA is $9.11 M
What is Quince Therapeutics quarterly SGA year-on-year change?
Over the past year, QNCX quarterly SGA has changed by -$1.28 M (-26.05%)
What is Quince Therapeutics TTM SGA?
The current TTM SGA of QNCX is -$1.37 B
What is the all time high TTM SGA for Quince Therapeutics?
Quince Therapeutics all-time high TTM SGA is -$32.83 M
What is Quince Therapeutics TTM SGA year-on-year change?
Over the past year, QNCX TTM SGA has changed by -$1.39 B (-7888.15%)